BRPI0520097A2 - composto ou estereoisÈmeros únicos, misturas de estereoisÈmeros, ou sais farmaceuticamente aceitáveis dos mesmos, composição farmacêutica, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo - Google Patents

composto ou estereoisÈmeros únicos, misturas de estereoisÈmeros, ou sais farmaceuticamente aceitáveis dos mesmos, composição farmacêutica, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo

Info

Publication number
BRPI0520097A2
BRPI0520097A2 BRPI0520097-0A BRPI0520097A BRPI0520097A2 BR PI0520097 A2 BRPI0520097 A2 BR PI0520097A2 BR PI0520097 A BRPI0520097 A BR PI0520097A BR PI0520097 A2 BRPI0520097 A2 BR PI0520097A2
Authority
BR
Brazil
Prior art keywords
pharmaceutically acceptable
stereoisomers
compound
mixtures
acceptable salts
Prior art date
Application number
BRPI0520097-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Daniel T W Chu
Donald R James
Bing Wang
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BRPI0520097A2 publication Critical patent/BRPI0520097A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0520097-0A 2005-02-25 2005-12-09 composto ou estereoisÈmeros únicos, misturas de estereoisÈmeros, ou sais farmaceuticamente aceitáveis dos mesmos, composição farmacêutica, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo BRPI0520097A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65674805P 2005-02-25 2005-02-25
US65671105P 2005-02-25 2005-02-25
PCT/US2005/044713 WO2006093548A1 (en) 2005-02-25 2005-12-09 Spiro-heterocyclic chromans, thiochromans and dihydroquinolines

Publications (1)

Publication Number Publication Date
BRPI0520097A2 true BRPI0520097A2 (pt) 2009-08-25

Family

ID=36941473

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0520097-0A BRPI0520097A2 (pt) 2005-02-25 2005-12-09 composto ou estereoisÈmeros únicos, misturas de estereoisÈmeros, ou sais farmaceuticamente aceitáveis dos mesmos, composição farmacêutica, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo

Country Status (8)

Country Link
US (1) US20080207588A1 (OSRAM)
EP (1) EP1856079A4 (OSRAM)
JP (1) JP2008531559A (OSRAM)
AU (1) AU2005328328A1 (OSRAM)
BR (1) BRPI0520097A2 (OSRAM)
CA (1) CA2600004A1 (OSRAM)
MX (1) MX2007010328A (OSRAM)
WO (1) WO2006093548A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2589363A1 (en) 2004-12-13 2006-06-22 Eli Lilly And Company Spiro derivatives as lipoxygenase inhibitors
WO2015027146A1 (en) 2013-08-22 2015-02-26 The General Hospital Corporation Inhibitors of human 12/15-lipoxygenase
CN105934246B (zh) 2013-11-18 2019-10-22 福马疗法公司 作为bet溴域抑制剂的四氢喹啉组成物
RU2720237C2 (ru) 2013-11-18 2020-04-28 Форма Терапеутикс, Инк. Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1261835A (en) 1984-08-20 1989-09-26 Masaaki Toda (fused) benz(thio)amides
GB8626344D0 (en) 1986-11-04 1986-12-03 Zyma Sa Bicyclic compounds
US5059609A (en) 1987-10-19 1991-10-22 Pfizer Inc. Substituted tetralins, chromans and related compounds in the treatment of asthma, arthritis and related diseases
US4950684A (en) 1988-05-20 1990-08-21 G. D. Searle & Co. 2,2-di-substituted benzopyran leukotriene-D4 antagonists
US5015661A (en) 1988-08-09 1991-05-14 Hoffmann-La Roche Inc. Chromanes and their pharmaceutical compositions and methods
WO1993009777A1 (en) 1991-11-22 1993-05-27 Lipogenics, Inc. Tocotrienols and tocotrienol-like compounds and methods for their use
US5250547A (en) * 1991-08-29 1993-10-05 Syntex (U.S.A.) Inc. Benzopyran derivatives
FR2695387B1 (fr) 1992-09-09 1994-10-21 Adir Nouveaux composés benzopyraniques, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
US5686389A (en) * 1994-04-13 1997-11-11 City Of Hope Growth inhibition of Erwinia amylovora
EP0785935A1 (en) 1994-10-13 1997-07-30 Pfizer Inc. Benzopyran and benzo-fused compounds, their preparation and their use as leukotriene b4' (ltb4) antagonists
CA2201742A1 (en) 1994-10-13 1996-04-25 Anthony Daniel Piscopio Benzopyran and benzo-fused compounds, their preparation and their use as leukotriene b4 (ltb4) antagonists
US5925673A (en) 1994-12-23 1999-07-20 Alcon Laboratories, Inc. Benzofurans and benzopyrans as cytoprotective agents
TW472051B (en) * 1997-05-23 2002-01-11 Chugai Pharmaceutical Co Ltd 2,3-dihydrobenzofuran derivatives
CA2589363A1 (en) * 2004-12-13 2006-06-22 Eli Lilly And Company Spiro derivatives as lipoxygenase inhibitors
JP2008531558A (ja) * 2005-02-25 2008-08-14 イーライ リリー アンド カンパニー 新規なリポオキシゲナーゼ阻害剤

Also Published As

Publication number Publication date
CA2600004A1 (en) 2006-09-08
EP1856079A1 (en) 2007-11-21
US20080207588A1 (en) 2008-08-28
MX2007010328A (es) 2008-03-13
WO2006093548A1 (en) 2006-09-08
EP1856079A4 (en) 2008-12-31
JP2008531559A (ja) 2008-08-14
AU2005328328A1 (en) 2006-09-08

Similar Documents

Publication Publication Date Title
BRPI0519013A2 (pt) composto ou esteroisÈmeros únicos, misturas de esteroisÈmeros, sais, tautÈmeros ou pró-drogas destes farmaceuticamente aceitáveis, composição farmacêutica, e, uso de um composto
BRPI0809977A8 (pt) Uso de um composto, compostos e composição farmacêutica que o contém
ATE360631T1 (de) Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors
BRPI0508540A8 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0410477A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, método para a profilaxia ou tratamento de uma condição quiral em um mamìfero, formulação farmacêutica, combinação, uso de um composto, e, processo para preparar um composto
ATE360630T1 (de) Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors
UA94901C2 (ru) Антибактериальные производные пиперидина
BRPI0908353B8 (pt) composto ou um sal farmaceuticamente aceitavel do mesmo e composição farmaceutica
BR0210711A (pt) Uso de um composto, composição farmacêutica, composto, e, processo para a preparação de um composto
UA96964C2 (ru) Соединения полициклической мочевины с антибактериальными свойствами
BR0209267A (pt) Pirimidinas fundidas como antagonistas do fator de liberação de corticotropina (crf)
BRPI0714803B8 (pt) compostos peptidomiméticos de smac, seus usos, e composição farmacêutica
BRPI0606793A8 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação e uso do mesmo, métodos para a inibição da atividade de trk, para o tratamento ou profilaxia de câncer e para a produção de um efeito anti-proliferativo em um animal de sangue quente, e, composição farmacêutica
CL2007001205A1 (es) Compuestos derivados de n-fenil-3-tio-4-fenil-azetedin-2-ona; procedimiento de preparacion; composicion farmaceutica; combinacion; uso en el tratamiento de una condicion hiperlipidemica, ateroesclerosis, alzheimer y tumores asociados a colesterol
BRPI0519979A2 (pt) composto ou estereoisÈmeros, misturas de estereoisÈmeros ou sais farmaceuticamente aceitáveis dos mesmos, composição farmacêutica, e, uso de um composto
BRPI0906444A8 (pt) compostos de 4-piridinona e seu uso para câncer
AR054347A1 (es) Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
BRPI0618479A2 (pt) pirrolpiridinas composição farmacêutica que as contém
BRPI0409884A (pt) compostos, composições farmacêuticas, método para o tratamento ou porfilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
BRPI0411092A (pt) benzo[b]tiofenos substituìdos com 3-arilsulfanila e com 3-heteroarilsulfanila como agentes terapêuticos
BRPI0409878A (pt) compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
MX2008008556A (es) Derivados de triterpenoquinonas y triterpenofenoles y su aplicacion para el tratamiento de tumores y enfermedades parasitarias.
BR0318659A (pt) derivados de prolina usados como ingredientes farmacêuticos ativos no tratamento de tumores
BRPI0515344A (pt) composto, composição farmacêutica, e, usos de uma quantidade eficaz de um composto 3-fosfoindol ou sal, pró-droga, estereoisÈmero, tautÈmero, n-óxido ou amina quaternária farmaceuticamente aceitável do mesmo e de uma quantidade de tratamento eficaz anti-hiv de um composto de 3-fosfoindol ou sal, pró-droga, estereo-isÈmero, tautÈmero, n-óxido ou amina quaternária farmaceuticamente aceitável do mesmo
BRPI0520097A2 (pt) composto ou estereoisÈmeros únicos, misturas de estereoisÈmeros, ou sais farmaceuticamente aceitáveis dos mesmos, composição farmacêutica, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO EM SUA FORMA AUTENTICADA; OU SEGUNDO PARECER DA PROCURADORIA NO 074/93, DEVE CONSTAR UMA DECLARACAO DE VERACIDADE, A QUAL DEVE SER ASSINADA POR UMA PESSOA DEVIDAMENTE AUTORIZADA A REPRESENTAR O INTERESSADO, DEVENDO A MESMA CONSTAR NO INSTRUMENTO DE PROCURACAO, OU NO SEU SUBSTABELECIMENTO.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.